🇺🇸 FDA
Pipeline program

Ventoclax

GD2H-2026-481

Phase 3 small_molecule active

Quick answer

Ventoclax for AML (Acute Myelogenous Leukemia) is a Phase 3 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
AML (Acute Myelogenous Leukemia)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials